<HTML>
<HEAD>
<TITLE>
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#02STP2349_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER"><FONT SIZE=2><B>As filed with the Securities and Exchange Commission on October&nbsp;1, 2002  </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<HR NOSHADE>
<HR NOSHADE>
<P ALIGN="CENTER"><FONT SIZE=5><B>U.S. SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>WASHINGTON, D.C. 20549  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=5><B>FORM S-8<BR>  </B></FONT><FONT SIZE=2><B>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=5><B>BIOSANTE PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2>(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="50%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=2><B>Delaware<BR> </B></FONT><FONT SIZE=2>(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD WIDTH="50%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=2><B>58-2301143<BR> </B></FONT><FONT SIZE=2>(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="50%" ALIGN="CENTER" VALIGN="BOTTOM"><BR><FONT SIZE=2><B>111 Barclay Boulevard, Suite 280<BR>
Lincolnshire, Illinois<BR> </B></FONT><FONT SIZE=2>(Address of Principal Executive Offices)</FONT></TD>
<TD WIDTH="50%" ALIGN="CENTER" VALIGN="BOTTOM"><BR><FONT SIZE=2><B>60069<BR> </B></FONT><FONT SIZE=2>(Zip Code)<BR></FONT>
</TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=5><B>AMENDED AND RESTATED 1998 STOCK OPTION PLAN<BR>  </B></FONT><FONT SIZE=2>(Full title of the plan) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B>Phillip B. Donenberg<BR>
Chief Financial Officer<BR>
BioSante Pharmaceuticals,&nbsp;Inc.<BR>
111 Barclay Boulevard, Suite 280<BR>
Lincolnshire, IL 60069<BR>
(847)&nbsp;478-0500<BR>  </B></FONT><FONT SIZE=2>(Name, address and telephone number,<BR>
including area code, of agent for service) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B>Approximate date of commencement of proposed sale to the public:<BR>
Immediately upon the filing of this registration statement  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B> CALCULATION OF REGISTRATION FEE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="36%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=1><B>Title of securities<BR>
to be registered</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=1><B>Amount to be<BR>
registered(1)</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=1><B>Proposed maximum<BR>
offering price per unit(2)</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=1><B>Proposed maximum<BR>
aggregate offering price</B></FONT></TD>
<TD WIDTH="1%" VALIGN="BOTTOM"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="BOTTOM"><FONT SIZE=1><B>Amount of<BR>
registration fee(2)</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM"><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="36%"><FONT SIZE=2>Common Stock, par value $0.0001 per share</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER"><FONT SIZE=2>300,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER"><FONT SIZE=2>$1,230,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER"><FONT SIZE=2>$4.10</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER"><FONT SIZE=2>$114.00(3)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM"><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>Represents
the increase in the total number of shares reserved for issuance under the registrant's Amended and Restated 1998 Stock Option Plan. An aggregate of 700,000 shares has been
previously registered under a registration statement on Form&nbsp;S-8 (File No.&nbsp;333-53384) In addition, pursuant to Rule&nbsp;416 under the Securities Act of 1933,
this registration statement includes an indeterminate number of additional shares that may be offered and sold as a result of anti-dilution provisions described in the registrant's Amended
and Restated 1998 Stock Option Plan.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>Estimated
solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule&nbsp;457(h) under the Securities Act as follows: (i)&nbsp;with
respect to options to purchase shares previously granted under the Amended and Restated 1998 Stock Option Plan, on the basis of the weighted average exercise price of these options, and
(ii)&nbsp;with respect to options to be granted under the plan based on the average between the high and low sales prices of the registrant's common stock on September&nbsp;27, 2002 on the
over-the-counter market, as reported by the Over-the-Counter Bulletin Board.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>BioSante
filed a registration statement on Form SB-2 (File No.&nbsp;333-87542) on May&nbsp;3, 2002 which was declared effective on August&nbsp;27, 2002.
The SEC filing fee previously paid in connection with the Form SB-2 was $920.00. Before that offering under the Form SB-2 was terminated pursuant to a
post-effective amendment that was declared effective on September&nbsp;12, 2002, BioSante sold shares at an aggregate purchase price of $4,500,000 for an SEC filing fee of $414.00.
Pursuant to Rule&nbsp;457(p), BioSante is offsetting the $120.00 filing fee due in connection with this registration statement against the remaining $506.00 of the filing fee from the terminated
offering.   </FONT></DD></DL>
<BR>
<HR NOSHADE>
<HR NOSHADE>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2090336",CP="BIOSANTE PHARMACEUTICALS, INC.",DN="1",CHK=106477,FOLIO='blank',FILE='DISK020:[02STP9.02STP2349]BA2349A.;5',USER='CPULLIA',CD=';1-OCT-2002;11:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_de2349_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="de2349_statement_under_general_instru__sta03068"> </A>
<A NAME="toc_de2349_1"> </A>
<BR></FONT><FONT SIZE=2><B>STATEMENT UNDER GENERAL INSTRUCTION E&#151;<BR>  REGISTRATION OF ADDITIONAL SECURITIES    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant, BioSante Pharmaceuticals,&nbsp;Inc., previously filed a registration statement on Form&nbsp;S-8 with the Securities and Exchange
Commission (SEC File No.&nbsp;333-53384) in connection with the registration of an aggregate of 700,000 (as adjusted to reflect a 1-for-10 reverse stock split
effective on May&nbsp;31, 2002) shares of BioSante's common stock to be issued under BioSante's Amended and Restated 1998 Stock Option Plan. BioSante amended this previous registration statement by
virtue of a post-effective amendment No.&nbsp;1 pursuant to Rule&nbsp;414 under the Securities Act of 1933, as amended, to reflect the reincorporation of BioSante from the State of
Wyoming to the State of Delaware. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to General Instruction E of Form&nbsp;S-8, this registration statement is filed by BioSante solely to register an additional 300,000 (as adjusted to reflect a
1-for-10 reverse stock split effective on May&nbsp;31, 2002) shares of common stock reserved for issuance under BioSante's Amended and Restated 1998 Stock Option Plan. These
increases were approved by BioSante's board of directors and stockholders. Pursuant to Instruction E, the contents of BioSante's previously filed registration statement on Form&nbsp;S-8
(SEC File No.&nbsp;333-53384) and the post-effective amendment No.&nbsp;1 thereto, including without limitation periodic reports that BioSante filed, or will file, after
this registration statement to maintain current information about BioSante, are hereby incorporated by reference into this registration statement pursuant to General Instruction E of
Form&nbsp;S-8. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="de2349_part_ii_information_req__de202474"> </A>
<A NAME="toc_de2349_2"> </A>
<BR></FONT><FONT SIZE=2><B>Part&nbsp;II    <BR>    <BR>    INFORMATION REQUIRED<BR>  IN THE REGISTRATION STATEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2><A
NAME="de2349_item_8._exhibits."> </A>
<A NAME="toc_de2349_3"> </A></FONT> <FONT SIZE=2><B>Item 8. Exhibits.    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="9%" ALIGN="LEFT"><FONT SIZE=1><B>Exhibit No.<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="89%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>5.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Opinion of Oppenheimer Wolff &amp; Donnelly LLP (filed herewith)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>23.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Consent of Deloitte &amp; Touche LLP (filed herewith)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>23.2</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Consent of Oppenheimer Wolff &amp; Donnelly LLP (included in Exhibit 5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>24.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Power of Attorney (included on the signature page to this registration statement)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2090336",CP="BIOSANTE PHARMACEUTICALS, INC.",DN="1",CHK=548874,FOLIO='1',FILE='DISK020:[02STP9.02STP2349]DE2349A.;2',USER='CPULLIA',CD=';1-OCT-2002;11:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_jc2349_1_2"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="jc2349_signatures"> </A>
<A NAME="toc_jc2349_1"> </A>
<BR></FONT><FONT SIZE=2><B>SIGNATURES    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements of filing on Form&nbsp;S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Lincolnshire, State of Illinois, on October&nbsp;1, 2002. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><B>BIOSANTE PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="44%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>STEPHEN M. SIMES</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Stephen M. Simes<BR></FONT> <FONT SIZE=2><I>Vice Chairman, President and Chief Executive Officer<BR>
(principal executive officer)</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="44%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>PHILLIP B. DONENBERG</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Phillip B. Donenberg<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer, Treasurer and Secretary<BR>
(principal financial and accounting officer)</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=3,EFW="2090336",CP="BIOSANTE PHARMACEUTICALS, INC.",DN="1",CHK=753377,FOLIO='2',FILE='DISK020:[02STP9.02STP2349]JC2349A.;3',USER='CPULLIA',CD=';1-OCT-2002;11:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_je2349_1_3"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="je2349_power_of_attorney"> </A>
<A NAME="toc_je2349_1"> </A>
<BR></FONT><FONT SIZE=2><B>POWER OF ATTORNEY    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose signature appears below constitutes and appoints Stephen M. Simes and Phillip B. Donenberg, and each of them, his or her true and lawful
attorney-in-fact and agent with full powers of substitution and resubstitution, for and in his or her name, place and stead, in any and all capacities, to sign any or all
amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary
to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed on October&nbsp;1, 2002 by the following persons in the capacities indicated. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="49%" ALIGN="LEFT"><FONT SIZE=1><B>Signature<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="49%" ALIGN="CENTER"><FONT SIZE=1><B>Title</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2>/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>STEPHEN M. SIMES</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Stephen M. Simes</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2>Vice Chairman, President and Chief Executive Officer</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>LOUIS W. SULLIVAN, M.D.</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Louis W. Sullivan, M.D.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Chairman of the Board</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>VICTOR MORGENSTERN</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Victor Morgenstern</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>EDWARD C. ROSENOW, III, M.D.</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Edward C. Rosenow, III, M.D.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>FRED HOLUBOW</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Fred Holubow</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>ROSS MANGANO</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Ross Mangano</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>ANGELA HO</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Angela Ho</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Director</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>PETER KJAER</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Peter Kjaer</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP"><FONT SIZE=2><BR>
Director</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=4,EFW="2090336",CP="BIOSANTE PHARMACEUTICALS, INC.",DN="1",CHK=123589,FOLIO='3',FILE='DISK020:[02STP9.02STP2349]JE2349A.;4',USER='CPULLIA',CD=';1-OCT-2002;11:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ka2349_biosante_pharmaceuticals,_inc.__bio03190"> </A>
<A NAME="toc_ka2349_1"> </A>
<BR></FONT><FONT SIZE=2><B>BIOSANTE PHARMACEUTICALS,&nbsp;INC.<BR>  REGISTRATION STATEMENT ON FORM&nbsp;S-8    <BR>    <BR>    INDEX TO EXHIBITS    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>Exhibit<BR>
No.</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="58%" ALIGN="CENTER"><FONT SIZE=1><B>Item</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="29%" ALIGN="CENTER"><FONT SIZE=1><B>Method of Filing</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>5.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="58%"><FONT SIZE=2>Opinion of Oppenheimer Wolff &amp; Donnelly LLP</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2>Filed herewith.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>23.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="58%"><FONT SIZE=2>Consent of Deloitte &amp; Touche LLP</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2>Filed herewith.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>23.2</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="58%"><FONT SIZE=2>Consent of Oppenheimer Wolff &amp; Donnelly LLP</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2>Included in Exhibit 5.1.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>24.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="58%"><FONT SIZE=2>Power of Attorney</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2>Included on the signature page to this registration statement.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=5,EFW="2090336",CP="BIOSANTE PHARMACEUTICALS, INC.",DN="1",CHK=863230,FOLIO='blank',FILE='DISK020:[02STP9.02STP2349]KA2349A.;4',USER='CPULLIA',CD=';1-OCT-2002;11:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="02STP2349_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_de2349_1">STATEMENT UNDER GENERAL INSTRUCTION E&#151; REGISTRATION OF ADDITIONAL SECURITIES</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de2349_2">Part II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></FONT><BR>
<UL>
<FONT SIZE=2><A HREF="#toc_de2349_3">Item 8. Exhibits.</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_jc2349_1">SIGNATURES</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_je2349_1">POWER OF ATTORNEY</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ka2349_1">BIOSANTE PHARMACEUTICALS, INC. REGISTRATION STATEMENT ON FORM S-8 INDEX TO EXHIBITS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=ESCHAEF,SEQ=,EFW="2090336",CP="BIOSANTE PHARMACEUTICALS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "a2090336zs-8.htm", "description": "S-8", "secsgml_size_bytes": 22344}]
{"company-data": {"conformed-name": "BIOSANTE PHARMACEUTICALS INC", "cik": "0001023024", "assigned-sic": "2836", "irs-number": "582301143", "state-of-incorporation": "WY", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-100238", "film-number": "02778868"}, "business-address": {"street1": "175 OLDE HALF DAY ROAD", "street2": "SUITE 123", "city": "LINCOLNSHIRE", "state": "IL", "zip": "60069", "phone": "8477932458"}, "mail-address": {"street1": "175 OLDE HALF DAY ROAD", "street2": "SUITE 123", "city": "LINCOLNSHIRE", "state": "IL", "zip": "60069"}, "former-company": {"former-conformed-name": "BEN ABRAHAM TECHNOLOGIES INC", "date-changed": "19991027"}}
QuickLinks
-- Click here to rapidly navigate through this document
As filed with the Securities and Exchange Commission on October 1, 2002
Registration No. 333-
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
BIOSANTE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
58-2301143
(I.R.S. Employer
Identification No.)
111 Barclay Boulevard, Suite 280
Lincolnshire, Illinois
(Address of Principal Executive Offices)
60069
(Zip Code)
AMENDED AND RESTATED 1998 STOCK OPTION PLAN
(Full title of the plan)
Phillip B. Donenberg
Chief Financial Officer
BioSante Pharmaceuticals, Inc.
111 Barclay Boulevard, Suite 280
Lincolnshire, IL 60069
(847) 478-0500
(Name, address and telephone number,
including area code, of agent for service)
Approximate date of commencement of proposed sale to the public:
Immediately upon the filing of this registration statement
CALCULATION OF REGISTRATION FEE
Title of securities
to be registered
Amount to be
registered(1)
Proposed maximum
offering price per unit(2)
Proposed maximum
aggregate offering price
Amount of
registration fee(2)
Common Stock, par value $0.0001 per share
300,000
$1,230,000
$4.10
$114.00(3)
(1)
Represents
the increase in the total number of shares reserved for issuance under the registrant's Amended and Restated 1998 Stock Option Plan. An aggregate of 700,000 shares has been
previously registered under a registration statement on Form S-8 (File No. 333-53384) In addition, pursuant to Rule 416 under the Securities Act of 1933,
this registration statement includes an indeterminate number of additional shares that may be offered and sold as a result of anti-dilution provisions described in the registrant's Amended
and Restated 1998 Stock Option Plan.
(2)
Estimated
solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(h) under the Securities Act as follows: (i) with
respect to options to purchase shares previously granted under the Amended and Restated 1998 Stock Option Plan, on the basis of the weighted average exercise price of these options, and
(ii) with respect to options to be granted under the plan based on the average between the high and low sales prices of the registrant's common stock on September 27, 2002 on the
over-the-counter market, as reported by the Over-the-Counter Bulletin Board.
(3)
BioSante
filed a registration statement on Form SB-2 (File No. 333-87542) on May 3, 2002 which was declared effective on August 27, 2002.
The SEC filing fee previously paid in connection with the Form SB-2 was $920.00. Before that offering under the Form SB-2 was terminated pursuant to a
post-effective amendment that was declared effective on September 12, 2002, BioSante sold shares at an aggregate purchase price of $4,500,000 for an SEC filing fee of $414.00.
Pursuant to Rule 457(p), BioSante is offsetting the $120.00 filing fee due in connection with this registration statement against the remaining $506.00 of the filing fee from the terminated
offering.
STATEMENT UNDER GENERAL INSTRUCTION E—
REGISTRATION OF ADDITIONAL SECURITIES
The registrant, BioSante Pharmaceuticals, Inc., previously filed a registration statement on Form S-8 with the Securities and Exchange
Commission (SEC File No. 333-53384) in connection with the registration of an aggregate of 700,000 (as adjusted to reflect a 1-for-10 reverse stock split
effective on May 31, 2002) shares of BioSante's common stock to be issued under BioSante's Amended and Restated 1998 Stock Option Plan. BioSante amended this previous registration statement by
virtue of a post-effective amendment No. 1 pursuant to Rule 414 under the Securities Act of 1933, as amended, to reflect the reincorporation of BioSante from the State of
Wyoming to the State of Delaware.
Pursuant
to General Instruction E of Form S-8, this registration statement is filed by BioSante solely to register an additional 300,000 (as adjusted to reflect a
1-for-10 reverse stock split effective on May 31, 2002) shares of common stock reserved for issuance under BioSante's Amended and Restated 1998 Stock Option Plan. These
increases were approved by BioSante's board of directors and stockholders. Pursuant to Instruction E, the contents of BioSante's previously filed registration statement on Form S-8
(SEC File No. 333-53384) and the post-effective amendment No. 1 thereto, including without limitation periodic reports that BioSante filed, or will file, after
this registration statement to maintain current information about BioSante, are hereby incorporated by reference into this registration statement pursuant to General Instruction E of
Form S-8.
Part II
INFORMATION REQUIRED
IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
Exhibit No.
Description
5.1
Opinion of Oppenheimer Wolff & Donnelly LLP (filed herewith)
23.1
Consent of Deloitte & Touche LLP (filed herewith)
23.2
Consent of Oppenheimer Wolff & Donnelly LLP (included in Exhibit 5.1)
24.1
Power of Attorney (included on the signature page to this registration statement)
1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements of filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Lincolnshire, State of Illinois, on October 1, 2002.
BIOSANTE PHARMACEUTICALS, INC.
By:
/s/
STEPHEN M. SIMES
Stephen M. Simes
Vice Chairman, President and Chief Executive Officer
(principal executive officer)
By:
/s/
PHILLIP B. DONENBERG
Phillip B. Donenberg
Chief Financial Officer, Treasurer and Secretary
(principal financial and accounting officer)
2
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Stephen M. Simes and Phillip B. Donenberg, and each of them, his or her true and lawful
attorney-in-fact and agent with full powers of substitution and resubstitution, for and in his or her name, place and stead, in any and all capacities, to sign any or all
amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary
to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed on October 1, 2002 by the following persons in the capacities indicated.
Signature
Title
/s/
STEPHEN M. SIMES
Stephen M. Simes
Vice Chairman, President and Chief Executive Officer
/s/
LOUIS W. SULLIVAN, M.D.
Louis W. Sullivan, M.D.
Chairman of the Board
/s/
VICTOR MORGENSTERN
Victor Morgenstern
Director
/s/
EDWARD C. ROSENOW, III, M.D.
Edward C. Rosenow, III, M.D.
Director
/s/
FRED HOLUBOW
Fred Holubow
Director
/s/
ROSS MANGANO
Ross Mangano
Director
/s/
ANGELA HO
Angela Ho
Director
/s/
PETER KJAER
Peter Kjaer
Director
3
BIOSANTE PHARMACEUTICALS, INC.
REGISTRATION STATEMENT ON FORM S-8
INDEX TO EXHIBITS
Exhibit
No.
Item
Method of Filing
5.1
Opinion of Oppenheimer Wolff & Donnelly LLP
Filed herewith.
23.1
Consent of Deloitte & Touche LLP
Filed herewith.
23.2
Consent of Oppenheimer Wolff & Donnelly LLP
Included in Exhibit 5.1.
24.1
Power of Attorney
Included on the signature page to this registration statement.
QuickLinks
STATEMENT UNDER GENERAL INSTRUCTION E— REGISTRATION OF ADDITIONAL SECURITIES
Part II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
SIGNATURES
POWER OF ATTORNEY
BIOSANTE PHARMACEUTICALS, INC. REGISTRATION STATEMENT ON FORM S-8 INDEX TO EXHIBITS